STERIS plc (STE) Q1 2027 Earnings Call Transcript
STERIS plc (STE) Q1 2027 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
STE
STERIS plcNYSEHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$22.40B
P/E Ratio
28.05
EPS
$8.19
Beta
0.91
52W High
$267.96
52W Low
$194.56
50-Day MA
$217.56
200-Day MA
$234.26
Dividend Yield
1.08%
Profit Margin
13.30%
Forward P/E
21.41
PEG Ratio
1.95
About STERIS plc
Steris Corporation is an American Irish-domiciled medical equipment company specializing in sterilization and surgical products for the US healthcare system.
Fundamentals
| Revenue (TTM) | $6.04B |
| Gross Profit (TTM) | $2.68B |
| EBITDA | $1.64B |
| Operating Margin | 19.20% |
| Return on Equity | 11.40% |
| Return on Assets | 6.80% |
| Revenue/Share (TTM) | $61.61 |
| Book Value | $73.92 |
| Price-to-Book | 3.16 |
| Price-to-Sales (TTM) | 3.71 |
| EV/Revenue | 4.026 |
| EV/EBITDA | 14.82 |
| Quarterly Earnings Growth (YoY) | 14.00% |
| Quarterly Revenue Growth (YoY) | 7.30% |
| Shares Outstanding | $97.50M |
| Float | $97.08M |
| % Insiders | 0.31% |
| % Institutions | 100.50% |
Historical Volatility
HV 10-Day
17.23%
HV 20-Day
27.33%
HV 30-Day
31.85%
HV 60-Day
28.12%
HV Rank
83.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($263.12 target)
3
Strong Buy4
Buy2
HoldLatest News
STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading
STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.
Zacks Investment Research8/6/2026Neutral
5 Quality Stocks Set to Reward Investors With Dividend Hikes
Recent dividend hikes from DRH, STE, BCC, KWR and WHD highlight financially solid companies as investors seek stability in a mixed market.
Zacks Investment Research8/6/2026Positive
STERIS Announces Financial Results for Fiscal 2027 First Quarter
DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal 2026. Constant currency organic revenue growth was 6% in the first quarter.
GlobeNewsWire8/5/2026Neutral
STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina
• This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries
GlobeNewsWire8/5/2026Neutral
STERIS Raises Dividend to $0.69 per share
DUBLIN, IRELAND, July 30, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.69 per share. This represents a $0.06 increase in the dividend and the Company's 21st consecutive year of dividend growth. The dividend is payable on September 25, 2026, to shareholders of record at the close of business on September 4, 2026.
GlobeNewsWire7/30/2026Neutral
STERIS' Q1 Earnings on Deck: What's in Store for the Stock?
STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.
Zacks Investment Research7/28/2026Positive
STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026
DUBLIN, IRELAND, July 27, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 first quarter results at 9:00 a.m. ET on August 6, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
GlobeNewsWire7/27/2026Neutral
Steris: A Good Moment To Buy Shares In This Sterilization Leader
Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18.
Seeking Alpha7/27/2026Positive
Why Steris (STE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research6/22/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STE and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026